TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04240795

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low lubricity (LL) hydrogels containing fibre-based beads
Description: The preload is made from kappa-carrageenan and alginate beads of 450 μm size. It contains no additional macronutrient but has food-grade watermelon flavor, color, and non-nutritive sweetener.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Low lubricity (LL) hydrogels containing fibre-based beads
Description: The preload is made from kappa-carrageenan and alginate beads of 450 μm size. It contains no additional macronutrient but has food-grade watermelon flavor, color, and non-nutritive sweetener.
Study: NCT04012164

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood sampling
Description: 5ml blood sampling

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: stool collection
Description: self stool collection (2g)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Participatory activity and contact investigation
Description: 30 human subjects will self-report daily activities and contacts with selected wild and domesticated animals for five months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anthropological and historical interviews
Description: Oral interviews on current and past practices and engagements with wild and domesticated animals will be conducted with the 30 human subjects who are recruited to self-report their activities (Participatory activity and contact investigation) and to provide blood and stool samples. Another 30 human subjects will be recruited only to participate in the same type of interviews, addressing past and present activities and relations with wild and domesticated animals.
Study: NCT02325869

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bell Balloon Catheter
Description: An angioplasty procedure to open the blockage in blood vessels will be performed. Standard angioplasty procedure includes local analgesia of the groin area and a small cut through which the procedure will be performed. An introducer sheath (thin tube) will be inserted. The Bell Balloon dilatation will then be inserted. The Bell Balloon works in fashion similar to standard balloon with the same physical and behavioral characteristics. Upon deflation, debris from the blockage is withdrawn into the cavity formed between the deflated balloon and its outer capsule. Then balloon is retracted and retrieved through the guiding catheter, together with the captured debris and trap it between the outer surface of the balloon and the inner surface of the membrane.
Study: NCT03140215

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: laryngeal mask insertion (Baska)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: laryngeal mask insertion (Baska)
Study: NCT02244151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decapeptyl® diario
Description: Decapeptyl® daily administration (Triptorelin acetate) and follicular puncture at 24, 30, 36 or 40 after administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decapeptyl® diario
Description: Decapeptyl® daily administration (Triptorelin acetate) and follicular puncture at 24, 30, 36 or 40 after administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decapeptyl® diario
Description: Decapeptyl® daily administration (Triptorelin acetate) and follicular puncture at 24, 30, 36 or 40 after administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Decapeptyl® daily
Description: Decapeptyl® daily OPU 36 hrs after GnRH administration
Study: NCT02159807

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: The dose of bupivacaine administered intrathecally during placement of the spinal anesthetic.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: The dose of bupivacaine administered intrathecally during placement of the spinal anesthetic.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: The dose of bupivacaine administered intrathecally during placement of the spinal anesthetic.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: 20 micrograms routinely administered in combination in the spinal anesthetic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: 20 micrograms routinely administered in combination in the spinal anesthetic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: 20 micrograms routinely administered in combination in the spinal anesthetic
Study: NCT05312957

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: erector spinae plane block
Description: Group ESP (Arm 1)The probe was placed craniocaudally in the parasagittal plane approximately 3 cm lateral to the T5 spinous process. The T5 transverse process is detected .When the block needle (Stimuplex B. Braun R, Melsungen, Germany) touched the transverse process, 0.5-1 mL of the 0.9% NaCl test dose was administered between the erector spinae muscle fascia and the vertebral transverse process, and the needle location was confirmed.Then, 20 ml of 0.25% bupivacaine was administered to this area, Group Control (Arm 2) :No intervention
Study: NCT00950170

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laboratory Tests
Description: Blood draws to determine the level of factor VIII activity before and after dosing at appropriate visits, and blood draws to determine levels of factor VIII inhibitor (antibody to factor VIII).
Study: NCT02479789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01254669

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BNI-brief Negotiated Interview
Description: use of a cognitive behavioral intervention to improve uptake of HPV vaccine
Study: NCT01054027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% phenylephrine and 0.2% cyclopentolate
Description: given as drops, prior to eye exam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% phenylephrine and 0.2% cyclopentolate
Description: given as drops, prior to eye exam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% phenylephrine and 0.2% cyclopentolate
Description: given as drops, prior to eye exam

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1% phenylephrine and 0.2% cyclopentolate
Description: given as drops, prior to eye exam
Study: NCT03429920

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Q CAN PLUS
Description: Active powder with fermented soy , 2 pouches per day, each pouch contains 12-15 gms of fermented soy

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sprouted brown rice protein with flavor (provided by BESO Biological Research, Inc.)
Study: NCT03730597

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: reverse shoulder arthroplasty
Description: prosthesis implantation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: reverse shoulder arthroplasty
Description: prosthesis implantation
Study: NCT03140215

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: laryngeal mask insertion (I-gel )

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: laryngeal mask insertion (I-gel )
Study: NCT02081755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus Dosing: 1.5 mg BID (3.0 mg/day) for 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus Dosing: 0.05 mg/kg BID for 12 months
Study: NCT01571063

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D3
Description: Vitamin D3, 2.100 IU/d p.o.
Study: NCT02063841

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: lead-free protective drape containing bismuth and antimony (RADPAD®)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: sterile identical sham drape
Study: NCT01571063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Vitamin D3, 2.100 IU/d p.o.
Study: NCT02081755

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Tacrolimus Dosing: 0.05 mg/kg BID for 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Myfortic
Description: Myfortic®: 360 mg to 1080 mg BID for 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CellCept
Description: CellCept: 500 mg to 1500 mg BID for 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imuran
Description: 0.5 mg/kg to 2 mg/kg QD for 12 months
Study: NCT03540550

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet based on inulin-rich vegetables
Description: During two weeks, healthy subjects were instructed to adhere to a controlled diet based on ITF-rich vegetables (±15 g ITF/day).
Study: NCT02043340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indocyanine green
Description: ICG group - scaling and root planing with application of 810 nm diode laser and ICG at a concentration of 5 mg/mL. Primary parameters included estimation of decrease in percentage of viable bacteria at baseline, immediate post treatment and end of 1 week and Lactate dehydrogenase (LDH) levels at baseline and end of 1 week. Secondary parameters included site-specific measures of plaque, gingivitis, pocket depth (PD) and clinical attachment loss (CAL) at specific time intervals.
Study: NCT01571063

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Tbl. p.o.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo Tbl. p.o.
Study: NCT00600171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW642444M
Description: GW642444M

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo mulit-dose dry powder inhaler
Study: NCT02367521

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Low Frequency Right sided repetitive transcranial magnetic stimulation (LFR rTMS)
Description: LFR rTMS will be delivered at the Brain Stimulation Program at The Johns Hopkins Hospital with a Magstim Super Rapid 2 stimulator with a focal double 70-mm air cooled coil. LFR rTMS will be administered to the Experimental Group.~Control patients will receive treatment using an identically appearing coil that produces the same sound and is the same weight as the active coil, but has negligible magnetic field strength.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham Comparator: Sham Treatment
Description: Control patients will receive treatment using an identically appearing coil that produces the same sound and is the same weight as the active coil, but has negligible magnetic field strength
Study: NCT03129308

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Sampling
Description: 4.5ml of blood will be collected and analyzed for the presence of cutaneous autoantibodies (indirect immunofluorescence, desmoglein1/3, BPAG1/2, collagenVII, and envoplakin ELISA)
Study: NCT02043340

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LASER
Description: LASER group - scaling and root planing with application of 810 nm diode laser Primary parameters included estimation of decrease in percentage of viable bacteria at baseline, immediate post treatment and end of 1 week and Lactate dehydrogenase (LDH) levels at baseline and end of 1 week. Secondary parameters included site-specific measures of plaque, gingivitis, pocket depth (PD) and clinical attachment loss (CAL) at specific time intervals.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scaling and Root Planing
Description: SRP group - scaling and root planning. Primary parameters included estimation of decrease in percentage of viable bacteria at baseline, immediate post treatment and end of 1 week and Lactate dehydrogenase (LDH) levels at baseline and end of 1 week. Secondary parameters included site-specific measures of plaque, gingivitis, pocket depth (PD) and clinical attachment loss (CAL) at specific time intervals.
Study: NCT02439359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CF-301
Description: Dose escalation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03059355

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UCMSCs
Description: Allogeneic Umbilical Cord Tissue derived MSCs (UCMSCs)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UCMSCs
Description: Allogeneic Umbilical Cord Tissue derived MSCs (UCMSCs)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UCMSCs
Description: Allogeneic Umbilical Cord Tissue derived MSCs (UCMSCs)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMMSCs
Description: Bone Marrow derived Mesenchymal Stem Cells (BMMSCs)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMMSCs
Description: Bone Marrow derived Mesenchymal Stem Cells (BMMSCs)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMMSCs
Description: Bone Marrow derived Mesenchymal Stem Cells (BMMSCs)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: a single administration of placebo delivered via peripheral intravenous infusion.
Study: NCT02726542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somatropin
Description: Norditropin (growth hormone) given by injection using a pen-device
Study: NCT01009372

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IPP
Description: Institution of intraoperative breaks for the surgeon with release of pneumoperitoneum for patient
Study: NCT03982134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDR001
Description: PDR001 is a humanized IgG4 antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Description: Panobinostat is a Histone deacetylase inhibitor (HDACi).
Study: NCT03372759

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: airtamponade
Description: airtamponade is applicated in the study group air

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: saline
Description: saline is left in the study Group saline
Study: NCT01954927

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: Gabapentin is supplied as an oral suspension. Patients randomized to the gabapentin arm will receive a single dose of gabapentin as soon after enrollment as feasible. The gabapentin dose will be given orally and will be approximately 15 mg/kg with a maximum dose of 900 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be prepared by the SJCRH pharmacy and will be similar in appearance, quantity and taste to the gabapentin drug. Patients randomized to the placebo arm will receive a single dose of placebo as soon after enrollment as feasible. The placebo dose will be given orally and will be approximately 15 mg/kg with a maximum dose of 900mg.
Study: NCT00689260

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: easypod
Description: Subjects is aware that the device records injection information that can be viewed by user
Study: NCT02104414

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exparel
Description: 266 mg/20mL Exparel (to be diluted with 10 mL sterile saline to make 30 mL)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine HCl with Epinephrine
Description: 75mg/30mL 0.25% Bupivacaine HCl with epinephrine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 30mL Normal Saline
Study: NCT04782167

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BRACE
Description: Balance training,Static balance:~1. Romberg with eye open \& eye close \[30 sec repeat 3 times\]~2. Tandem standing with eye open then with eye close. Right foot front first, then left foot front \[10 Sec repeat 3 times\]~3. Single leg stance 5 repetition with sec.~Static/Dynamic/Anti-cipatory Postural Control:~1. Sit to stand: 5 repetition~2. Functional reach test: forward, sideways \& cross reach, practice 1 min for each~3. TUG test: with distance of 10 feet \& time 10 sec. practice 2 min Cognitive exercises~1) Count reverse from 50 Repeat with eyes open and close Reps of 30s for each 2) Push wall and reverse count from 20 3) Remember 5 words, Name 5 animals, Repeat 5 words

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Propirioceptive training
Description: 1st Phase - Steady phase (1st set: Eyes Open, 2nd set: Eyes Close) Preserve standup position Equally heels up and down Preserve standup on one leg by turns
Study: NCT00430755

Intervention type: DEVICE
Group type: OTHER
Intervention: Computer-assisted history
Description: Methods The intervention was use of an expert system to acquire medical histories by direct interview of patients.~Description of the software program - The program tested in this study consisted of a data acquisition \[history-taking\] component and a data analysis component. The data acquisition component was constructed on the basis of established principles of pathophysiology. Medical knowledge was formalized as software algorithms that were machine-readable by representing the knowledge as branched chain decision trees.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: physician taken history
Description: Convential history taking by physicians

Intervention type: OTHER
Group type: OTHER
Intervention: Computer-assisted history taking
Study: NCT02733029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sonazoid
Description: Sonazoid (GE Healthcare) is a contrast agent that is a lipid-stabilized suspension of perfluorobutane microbubbles

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: contrast enhanced ultrasonography
Description: Injection of intravenous ultrasound contrast
Study: NCT03902080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vibegron
Description: oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral administration
Study: NCT00450944

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: deglycosylated ricin A chain-conjugated anti-CD19/anti-CD22 immunotoxins
Study: NCT03346174

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AAD
Description: In this controlled trial with intra-subject design infants will be studied using multichannel intraluminal impedance pH (pH-MII) monitoring , during which they receive one 20 min session of AAD . The number of reflux episodes (RE) is the outcome measure. The results obtained during and 20 min after the intervention will be compared to a period of 20 min before treatment ( control ).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BAAD
Description: In this controlled trial with intra-subject design infants will be studied using multichannel intraluminal impedance pH (pH-MII) monitoring , during which they receive one 20 min session of BAAD . The number of reflux episodes (RE) is the outcome measure. The results obtained during and 20 min after the intervention will be compared to a period of 20 min before treatment ( control ).
Study: NCT00463476

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live, Attenuated Japanese Encephalitis SA 14-14-2 Vaccine (LJEV)
Description: Manufactured by Chengdu Institute of Biological Products (CDIBP), Chengdu, China; batch 200611A078-1. Administered subcutaneously in the right upper arm using 23 gauge needles.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live, Attenuated Japanese Encephalitis SA 14-14-2 Vaccine (LJEV)
Description: Manufactured by Chengdu Institute of Biological Products (CDIBP), Chengdu, China; batch 200611A078-1. Administered subcutaneously in the right upper arm using 23 gauge needles.
Study: NCT01505894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306
Description: Film-coated tablet
Study: NCT00689260

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: easypod
Description: Subjects is not aware that the device records injection information that can be viewed by user
Study: NCT01486082

Intervention type: OTHER
Intervention: OCA 10
Description: A group will be treated with omeprazole (20 mg / 12 h), amoxicillin (1 g/ 12 h)and clarithromycin (500 mg/12 h) for 10 days (as following current guides) without having a previous antibiogram, and the other group will be treated after antibiotic susceptibility.

Intervention type: OTHER
Intervention: OCA 10
Description: A group will be treated with omeprazole (20 mg / 12 h), amoxicillin (1 g/ 12 h)and clarithromycin (500 mg/12 h) for 10 days (as following current guides) without having a previous antibiogram, and the other group will be treated after antibiotic susceptibility.
Study: NCT01221285

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: German cockroach (Blattella germanica) allergenic extract
Description: Participants received weekly escalating doses of glycerinated German cockroach allergenic extract administered via the subcutaneous route up to a Maximum Study Dose of 0.6 mL of extract at a concentration of 1:20 wt/vol.
Study: NCT00842907

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral isotretinoin
Description: one 20.0 mg capsule, once a day, every other day, during 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tretinoin
Description: 0.05% tretinoin cream applied on face and forearms, once a day, in the night, during 24 weeks
Study: NCT06531889

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: classical physiotherapy program
Description: Classical physiotherapy program=Classical physiotherapy program included transcutaneous electrical nerve stimulation, infrared radiation for 15 min, continuous ultrasound for 5 min and home exercise program. For active assistive shoulder range of motion (ROM), home exercises included the Codman exercise, flexion exercise at the ladder, and the Wand exercise, as well as some strengthening and stretching exercises performed at the pain limit with 10 repetitions twice a day (six weeks)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: classical physiotherapy program
Description: Classical physiotherapy program=Classical physiotherapy program included transcutaneous electrical nerve stimulation, infrared radiation for 15 min, continuous ultrasound for 5 min and home exercise program. For active assistive shoulder range of motion (ROM), home exercises included the Codman exercise, flexion exercise at the ladder, and the Wand exercise, as well as some strengthening and stretching exercises performed at the pain limit with 10 repetitions twice a day (six weeks)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core Stabilization Exercises
Description: The interventions of the core exercise were applied when the patient lay on his/her back with his/her knees at flexion. The number of repeats for each exercise was five, and these exercises were done 3 times a week for 6 weeks with the same physiotherapist. The further steps in the exercises were extended according to the activation duration of the core muscles, and this extension was elongated 5 s
Study: NCT02730195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Given PO